SCHEMBL23928225

SCHEMBL23928225

O=C(O)NCCc1ccc(NC(=O)CN2CCC(F)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
KDM4E B2RXH2 2/20 0.54
TDP1 Q9NUW8 1/20 0.54
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
HRH3 Q9Y5N1 3/20 0.52
SMN1; SMN2 Q16637 6/20 0.49
HTT P42858 3/20 0.49
LMNA P02545 3/20 0.49
TSHR P16473 1/20 0.49
RAB9A P51151 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ATM Q13315 1/20 0.48
THRB P10828 1/20 0.48
SMYD3 Q9H7B4 1/20 0.47
RECQL P46063 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
NPC1 O15118 1/20 0.46
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23928218 0.87 NPC1 (0.60) ALDH1A1KDM4ETDP1MEN1KMT2A
SCHEMBL23928215 0.84 HRH3 (0.52) ALDH1A1KDM4ETDP1MEN1KMT2A
SCHEMBL23928157 0.84 SMYD3 (0.53) ALDH1A1KDM4ETDP1MEN1KMT2A
SCHEMBL23291325 0.83 NAMPT (0.55) ALDH1A1KDM4ETDP1MEN1KMT2A
SCHEMBL16581996 0.77 MC4R (0.50) ALDH1A1KDM4ETDP1MEN1KMT2A
SCHEMBL23291260 0.76 SMN1; SMN2 (0.50) ALDH1A1KDM4EMEN1KMT2AHRH3
SCHEMBL23291148 0.75 ALDH1A1 (0.63) ALDH1A1MEN1KMT2ALMNATSHR
SCHEMBL23928149 0.75 LMNA (0.67) SMN1; SMN2HTTLMNATSHRRAB9A
SCHEMBL16620097 0.74 NPC1 (0.56) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL19876843 0.73 CNR1 (0.50) MEN1KMT2ASMN1; SMN2HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ADORA2A, ADORA1, ADORA3 ALDH1A1 571/4885KDM4E 3952/4885TDP1 1756/4885
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 ALDH1A1 571/4885KDM4E 3952/4885TDP1 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.